About
Contact & Profiles
A5093725821
Research Areas
- Asthma and respiratory diseases
- Allergic Rhinitis and Sensitization
- Dermatology and Skin Diseases
NBE Therapeutics (Switzerland)
2024
Inhibition of IL-4/IL-13 signaling has dramatically improved the treatment atopic dermatitis (AD). In many patients, however, clinical responses are slow to develop and remain modest. Indeed, some symptoms AD dependent on IL-31, which is only partially reduced by inhibition. Thus, there an unmet need for treatments that concomitantly block IL-31 pathways. We engineered NM26-2198, a bispecific tetravalent antibody designed accomplish this task. reporter cell lines, NM26-2198 inhibited with...
10.1016/j.xjidi.2024.100258
article
EN
cc-by-nc-nd
JID Innovations
2024-01-16
Coming Soon ...